Abstract
We report 12 years’experience with histocompatible, related donor marrow transplantation for 123 patients with acute lymphoblastic leukaemia; 104 second remission. Four regimens were studied: cyclophosphamide (Cy)+total body irradiation (TBI) (n= 35); Cy + fractionated TBI (n= 45); TBI + high‐dose cytarabine (n= 15); and hyperfractionated TBI + Cy (n= 28). 45 patients survive (34 ± 9%: 95% confidence interval) between 1 and 12·7 years (median 7·8 years) following BMT and 29 ± 8% survive leukaemia‐free. Significantly improved disease‐free survival was observed in patients with an initial WBC < 50 x 109/l (P= 0·02). Conditioning regimens tested yielded similar outcomes, though TBI/cytarabine led to greater treatment associated mortality. Leukaemia relapse was the most frequent cause of failure in 56 ± 11%; median time of relapse 8 months following BMT, none beyond 2·2 years. Relapse was more frequent with higher WBC, shorter initial remission and previous CNS leukaemia. Acute and/or chronic GVHD was associated with a strong trend (P= 0·06) towards less relapse. Allogeneic BMT may be curative for a substantial fraction of patients with ALL, but additional anti‐leukaemic measures beyond these conditioning modifications tested will be required to prevent post‐transplant leukaemia recurrence.
Original language | English (US) |
---|---|
Pages (from-to) | 62-69 |
Number of pages | 8 |
Journal | British journal of haematology |
Volume | 86 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1994 |
Keywords
- acute lymphoblastic leukaemia
- allogeneic BMT
- risk factors